Business Standard

Sun Pharma gains ahead of Q2 results

The company may report 29% y-o-y growth in its consolidated net profit at Rs 772 crore in Q2.

SI Reporter  |  Mumbai 

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

The stock opened at Rs 700 and hit a high of Rs 714 on the NSE. A combined 684,427 shares have changed hands on the counter so far against an average 609,000 shares that were traded daily in past ten trading days.

According to an average analyst estimates, may report 29% year-on-year growth in its consolidated net profit at Rs 772 crore in the September 2012 quarter. The company had reported profit of Rs 598 crore in previous year quarter.

“Sun Pharma is likely to report strong revenue growth at 50% led by 18% growth in domestic formulations, 49% growth in Taro US revenues and niche launches in US viz. Lipodex and Stalevo. Operating margins are likely to expand by over 600 bps to 40%,” according to analyst at Emkay Global Financial Services.

RECOMMENDED FOR YOU

Sun Pharma gains ahead of Q2 results

The company may report 29% y-o-y growth in its consolidated net profit at Rs 772 crore in Q2.

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

The stock opened at Rs 700 and hit a high of Rs 714 on the NSE. A combined 684,427 shares have changed hands on the counter so far against an average 609,000 shares that were traded daily in past ten trading days.

According to an average analyst estimates, may report 29% year-on-year growth in its consolidated net profit at Rs 772 crore in the September 2012 quarter. The company had reported profit of Rs 598 crore in previous year quarter.

“Sun Pharma is likely to report strong revenue growth at 50% led by 18% growth in domestic formulations, 49% growth in Taro US revenues and niche launches in US viz. Lipodex and Stalevo. Operating margins are likely to expand by over 600 bps to 40%,” according to analyst at Emkay Global Financial Services.

image

LIVE MARKET

BSE 25696.44

-586.65 (-2.23 %)

NSE 7785.85

-185.45 (-2.33%)

Widgets Magazine

STOCK WATCH

Company Price() Chg(%)
Essar Oil 197.35 12.67
Essar Ports 95.35 7.44
Rolta India 101.30 5.25
UPL 525.60 4.55
PMC Fincorp 1.42 4.41
> More on BSE Gainers
Company Price() Chg(%)
Rolta India 101.45 5.35
UPL 525.85 4.64
Guj Pipavav Port 178.00 4.34
United Breweries 886.00 3.64
Guj Fluorochem 682.90 3.41
> More on NSE Gainers
Company Price() Chg(%)
Sunrise Asian 211.30 -9.97
Motil.Oswal.Fin. 302.10 -7.90
Eveready Inds. 264.90 -7.78
Symphony 1857.00 -7.69
ISGEC Heavy 5236.85 -7.26
> More on BSE Gainers
Company Price() Chg(%)
MT Educare 126.55 -7.53
Motil.Oswal.Fin. 304.00 -7.43
JSW Energy 70.40 -7.43
Gammon India 12.75 -7.27
Punjab Natl.Bank 134.80 -6.94
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price